Bicycle Therapeutics plc (NASDAQ:BCYC) Insider Sells $69,646.87 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) insider Santiago Arroyo sold 4,943 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the sale, the insider now owns 69,057 shares of the company’s stock, valued at $973,013.13. This represents a 6.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Bicycle Therapeutics Stock Performance

Bicycle Therapeutics stock traded down $0.01 during trading hours on Monday, hitting $14.88. 289,310 shares of the stock were exchanged, compared to its average volume of 435,603. The stock has a market capitalization of $1.03 billion, a P/E ratio of -4.52 and a beta of 0.92. The business’s 50-day moving average is $19.27 and its two-hundred day moving average is $21.86. Bicycle Therapeutics plc has a 12 month low of $12.17 and a 12 month high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.04. The company had revenue of $2.68 million during the quarter, compared to analyst estimates of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s quarterly revenue was down 50.0% compared to the same quarter last year. During the same period last year, the company posted ($1.26) earnings per share. On average, equities analysts predict that Bicycle Therapeutics plc will post -3.05 earnings per share for the current fiscal year.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds have recently modified their holdings of the company. Armistice Capital LLC raised its holdings in shares of Bicycle Therapeutics by 17.9% during the second quarter. Armistice Capital LLC now owns 1,972,000 shares of the company’s stock worth $39,913,000 after acquiring an additional 300,000 shares during the period. Westfield Capital Management Co. LP increased its holdings in Bicycle Therapeutics by 21.5% during the third quarter. Westfield Capital Management Co. LP now owns 1,850,945 shares of the company’s stock worth $41,887,000 after buying an additional 327,089 shares during the last quarter. First Light Asset Management LLC grew its holdings in Bicycle Therapeutics by 16.1% during the second quarter. First Light Asset Management LLC now owns 1,384,768 shares of the company’s stock worth $28,028,000 after purchasing an additional 191,717 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Bicycle Therapeutics by 1,438.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 899,799 shares of the company’s stock worth $20,362,000 after acquiring an additional 841,299 shares during the last quarter. Finally, Avoro Capital Advisors LLC acquired a new stake in shares of Bicycle Therapeutics during the 2nd quarter worth about $14,168,000. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BCYC has been the subject of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicycle Therapeutics in a research report on Monday, September 9th. B. Riley decreased their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Stephens assumed coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research note on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $35.25.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.